{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":3185,"total_is_capped":false,"direct_labels_cover":13,"predictions_cover":3185,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"68f5e8d0123a","filters":{"topic":"Hepatitis C virus research"}},"results":[{"id":"W2027545702","doi":"10.1056/nejmoa020047","title":"Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection","year":2002,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6397,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Nutrasource","funders":"National Center for Research Resources","keywords":"Ribavirin; Medicine; Peginterferon alfa-2a; Internal medicine; Gastroenterology; Interferon alfa; Alpha interferon; Hepatitis C; Hepatitis C virus; Placebo; Interferon; Immunology; Virus; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06331394442343537,"gpt":0.3399126845956345,"spread":0.2765987401721992,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009856916,0.0002019165,0.0006796132,0.0004419509,0.00008188924,0.00001725011,0.0001343767,0.0001189173,0.002661267],"category_scores_gemma":[0.001239712,0.0001439004,0.000157022,0.0002390542,0.0001312474,0.0001765445,0.00002639104,0.0006260991,0.00006413593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006160768,"about_ca_system_score_gemma":0.0002663193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003128622,"about_ca_topic_score_gemma":0.00320464,"domain_scores_codex":[0.9978276,0.0001152326,0.0007182217,0.0001876707,0.0007548649,0.0003964072],"domain_scores_gemma":[0.9982082,0.0002980886,0.0002875912,0.0002384304,0.0004143249,0.0005534063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0011271,0.0001326079,0.03433419,0.000226115,0.0002461229,0.0004305503,0.001084462,0.00007144854,0.01054463,0.00006568684,0.1402442,0.8114929],"study_design_scores_gemma":[0.09021267,0.01640195,0.01985146,0.001383066,0.0003453475,0.002107853,0.00001669496,0.005820223,0.002706266,0.0002725607,0.8606668,0.0002151739],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9336953,0.009384773,0.01916237,0.02606008,0.002375561,0.001003467,0.00001651172,0.00006315733,0.008238847],"genre_scores_gemma":[0.9659842,0.01806078,0.0004249587,0.0005074859,0.01132689,0.000009540294,0.00001219013,0.00004457185,0.003629381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8112777,"threshold_uncertainty_score":0.9982504,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143559032","doi":"10.1056/nejmoa1010494","title":"Boceprevir for Untreated Chronic HCV Genotype 1 Infection","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2502,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Genentech; Gilead Sciences; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Pfizer; Bristol-Myers Squibb","keywords":"Boceprevir; Medicine; Ribavirin; Hepatitis C virus; Genotype; Virology; Telaprevir; Protease inhibitor (pharmacology); Chronic hepatitis; Virus; Internal medicine; Immunology; Viral load; Gene; Antiretroviral therapy; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.08955031681378442,"gpt":0.3491844877614537,"spread":0.2596341709476693,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009973584,0.0001281405,0.0004606655,0.0003042942,0.00004717926,0.000004549824,0.00008715407,0.00008770043,0.001784069],"category_scores_gemma":[0.001076619,0.00008175012,0.00009209617,0.0002265335,0.00008805676,0.0000967856,0.00001407223,0.000360036,0.00002802223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001765167,"about_ca_system_score_gemma":0.0005044276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006757089,"about_ca_topic_score_gemma":0.0001766754,"domain_scores_codex":[0.9986299,0.00007478514,0.0004971995,0.0001182673,0.0004232228,0.0002566027],"domain_scores_gemma":[0.9985879,0.0001405412,0.0002126551,0.0001728039,0.000476089,0.0004100285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002628983,0.0001102912,0.06108641,0.0001931398,0.0002885307,0.0002511478,0.001284222,0.000003546801,0.008497988,0.0001721868,0.02591481,0.8995687],"study_design_scores_gemma":[0.1040479,0.0188776,0.07311225,0.001164903,0.000657949,0.001180554,0.00003316191,0.0002734514,0.006483428,0.00117684,0.7928119,0.0001799941],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9369238,0.007571747,0.01295958,0.00746709,0.001620997,0.001117178,0.00000659025,0.000064358,0.03226864],"genre_scores_gemma":[0.988314,0.00261083,0.001051355,0.0002910157,0.00638945,0.000003978158,0.00001007905,0.00002901314,0.001300236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8993887,"threshold_uncertainty_score":0.9991285,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125963799","doi":"10.1056/nejmoa1012912","title":"Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2377,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Duke Clinical Research Institute; Vertex Pharmaceuticals","keywords":"Ribavirin; Telaprevir; Medicine; Gastroenterology; Internal medicine; Placebo; Hepatitis C virus; Peginterferon alfa-2a; Virology; Hepatitis C; Virus; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.06802081010946999,"gpt":0.3339683782920247,"spread":0.2659475681825547,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001241793,0.0001819591,0.0006432777,0.0003799479,0.00006389384,0.000007729943,0.0001183609,0.0001135989,0.001701126],"category_scores_gemma":[0.001481377,0.0001205341,0.0001378801,0.0002793959,0.0001237818,0.0001545045,0.00002006321,0.0004434548,0.00002846739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002752568,"about_ca_system_score_gemma":0.0006049195,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007795536,"about_ca_topic_score_gemma":0.003352611,"domain_scores_codex":[0.9980896,0.0001266804,0.000715988,0.0001622711,0.0005493126,0.0003561664],"domain_scores_gemma":[0.9981511,0.0002059968,0.0003233877,0.0002278882,0.0005451441,0.0005465458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001871924,0.0001523557,0.2290534,0.0002706164,0.0003344957,0.0003936245,0.001557501,0.000003846621,0.006929866,0.0000939517,0.0225219,0.7368165],"study_design_scores_gemma":[0.1368345,0.03726306,0.2021089,0.003314758,0.001269066,0.003248468,0.00002273514,0.0004501364,0.0148251,0.001363282,0.5989427,0.0003572289],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703501,0.006042129,0.009673299,0.002542232,0.00105983,0.001142709,0.000008781019,0.00005689423,0.009123981],"genre_scores_gemma":[0.9710428,0.01988436,0.00125968,0.0003261793,0.00610191,0.00001251477,0.00001580406,0.00004431279,0.001312466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7364593,"threshold_uncertainty_score":0.9992114,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157916750","doi":"10.1056/nejmoa1209026","title":"Treatment of HCV Infection by Targeting MicroRNA","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2186,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Placebo; Liter; Adverse effect; Hepatitis C virus; Internal medicine; RNA; Gastroenterology; Kilogram; Virus; Pharmacology; Immunology; Virology; Body weight; Biology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02503201688067588,"gpt":0.3195664327089914,"spread":0.2945344158283155,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003793633,0.0001124517,0.0004850732,0.0002092051,0.00002685584,0.000005234768,0.00005019239,0.00005847871,0.001354181],"category_scores_gemma":[0.0005447185,0.00006593409,0.00007588464,0.0001601075,0.00008021446,0.00009231061,0.000008093558,0.0001932703,0.00002494846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001250103,"about_ca_system_score_gemma":0.0001589121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002803262,"about_ca_topic_score_gemma":0.00002144374,"domain_scores_codex":[0.9985893,0.00008725523,0.000567519,0.00008441861,0.0004848421,0.000186688],"domain_scores_gemma":[0.998722,0.0001586309,0.0002755313,0.0001118101,0.0003791092,0.0003529787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002467853,0.0001624193,0.1154217,0.00004623562,0.000146742,0.00007855771,0.0008546545,0.000002250962,0.1523609,0.000005028329,0.08003888,0.6506358],"study_design_scores_gemma":[0.068205,0.01318806,0.02326186,0.0004857372,0.0002229513,0.0005115158,0.0001164813,0.0001356777,0.02729963,0.00013605,0.866329,0.0001080916],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795125,0.003095185,0.0004666431,0.01111717,0.0003168496,0.0002529438,0.000001892665,0.000008585504,0.005228281],"genre_scores_gemma":[0.9919141,0.003804779,0.0005904969,0.0001266291,0.002351172,0.000002087932,0.000008819258,0.0000153337,0.001186615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.78629,"threshold_uncertainty_score":0.9995587,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2578013986","doi":"10.1016/s2468-1253(16)30181-9","title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","year":2016,"lang":"en","type":"review","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":2032,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cliniques Universitaires Saint-Luc; British Columbia Centre for Disease Control; Kwame Nkrumah University of Science and Technology; Merck Sharp and Dohme; Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu; Medical Research Council; Abbott Diagnostics; Tartu Ülikool; University of Cape Town; Universitas Indonesia; Kementerian Kesihatan Malaysia; Universidade de São Paulo; Monash University; Universidad de Buenos Aires; Rigshospitalet; Instituto Mexicano del Seguro Social; Aalborg Universitetshospital; Tehran University of Medical Sciences and Health Services; Universiti Malaya; University of New South Wales; KU Leuven; Bundesministerium für Gesundheit; Ariad Pharmaceuticals; National Taiwan University Hospital; Fakultas Kedokteran, Universitas Indonesia; Aalborg Universitet; University of Ulsan; Cairo University; King Saud University; Intercept Pharmaceuticals; National Taiwan University; Institut National de la Santé et de la Recherche Médicale; Universität Wien; University of Nottingham; Háskóli Íslands; Ministerio de Economía y Competitividad; Bristol-Myers Squibb; Hadassah Medical Organization; Cleveland Clinic; Cilag; Ankara Universitesi; Ain Shams University; Università degli Studi di Palermo; Dokuz Eylül Üniversitesi; Nottingham University Hospitals NHS Trust; University College London; Alexion Pharmaceuticals; Medizinische Universität Wien; National and Kapodistrian University of Athens; Karolinska Institutet; Bill and Melinda Gates Foundation; Falk Foundation; Istituto Superiore di Sanità; Gilead Sciences; Dalhousie University; GlaxoSmithKline; Akershus Universitetssykehus; Trimbos-instituut; American University of Beirut; Alnylam Pharmaceuticals; National Institute for Health and Care Research","keywords":"Genotype; Virology; Hepatitis C virus; Medicine; Hepatitis C; Distribution (mathematics); Biology; Virus; Genetics; Mathematics","retraction":null,"screen_n_in":null,"score":{"opus":0.05674993887356897,"gpt":0.3716005843209279,"spread":0.3148506454473589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001215603,0.0005429654,0.003388002,0.0002848991,0.00009600396,0.0000153014,0.0004076676,0.0005787975,0.00006238867],"category_scores_gemma":[0.0001188567,0.0003800057,0.000260229,0.0004131487,0.0006510712,0.00008731133,0.0004187862,0.0009024721,0.00005217995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007391334,"about_ca_system_score_gemma":0.0003745103,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.008205084,"about_ca_topic_score_gemma":0.03369722,"domain_scores_codex":[0.9942333,0.002121909,0.001304643,0.0009017988,0.0003749325,0.001063377],"domain_scores_gemma":[0.9978223,0.0002552083,0.0005965859,0.0009426086,0.0002101294,0.000173145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005362274,0.0003327139,0.9149151,0.003724225,0.0003271227,0.0001641472,0.0000424461,0.000005401702,6.795563e-7,0.00002911027,0.0003364633,0.07958637],"study_design_scores_gemma":[0.01080468,0.01190965,0.5839362,0.01275247,0.003568047,0.003346705,0.00001522106,0.003666389,9.672551e-7,0.0004211584,0.3686999,0.0008785999],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3515584,0.6390433,0.004938466,0.0002067454,0.0003980571,0.002907839,0.0008052447,0.0000624001,0.00007955159],"genre_scores_gemma":[0.2046463,0.7944597,0.00004259351,0.00008570187,0.0002140244,0.0003759582,0.0001134102,0.00003617921,0.00002617078],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3683635,"threshold_uncertainty_score":0.9998652,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047208492","doi":"10.1002/hep.20119","title":"Diagnosis, management, and treatment of hepatitis C†","year":2004,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1718,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Guideline; Hepatitis C virus; Hepatitis C; MEDLINE; Immunology; Internal medicine; Intensive care medicine; Family medicine; Pathology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.0390272345138234,"gpt":0.3325017658209528,"spread":0.2934745313071294,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003853923,0.0000952915,0.0003065488,0.0001480395,0.00002977014,0.000003327407,0.00003581454,0.00007092481,0.0002033015],"category_scores_gemma":[0.00002447301,0.00008174543,0.00004526249,0.0001237923,0.000154894,0.00002602929,0.0000332565,0.00004249055,0.00006583787],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001177452,"about_ca_system_score_gemma":0.00005195307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00214452,"about_ca_topic_score_gemma":0.0008972205,"domain_scores_codex":[0.999238,0.00003130168,0.0001806792,0.0001990345,0.0001278692,0.0002231583],"domain_scores_gemma":[0.9995491,0.00004264968,0.00003258139,0.0002252367,0.00003797312,0.0001124633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00004102153,0.000274227,0.9025874,0.00006855285,0.000100519,0.0005893511,0.000125229,2.547276e-7,0.00005640544,0.003699697,0.0002467347,0.09221062],"study_design_scores_gemma":[0.007527966,0.002644439,0.7816091,0.0001049475,0.0001757417,0.0002526962,0.00004115394,0.000081518,0.01368919,0.001968682,0.1917181,0.0001863939],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863961,0.001350776,0.00006570882,0.001351098,0.00005168448,0.000398498,0.00001290846,0.00003001646,0.01034316],"genre_scores_gemma":[0.9709138,0.0265084,0.001888018,0.0001597297,0.00002450101,0.0001420594,0.00001348845,0.00001351555,0.0003365386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1914714,"threshold_uncertainty_score":0.3333482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077103006","doi":"10.1002/hep.20819","title":"Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *","year":2005,"lang":"en","type":"review","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1505,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institut National de Santé Publique du Québec","funders":"","keywords":"Nomenclature; Genotype; Hepatitis C virus; Typing; Virology; Biology; NS5B; Hepatitis C; Genetics; Computational biology; Hepacivirus; Virus; Gene; Taxonomy (biology)","retraction":null,"screen_n_in":null,"score":{"opus":0.09450721349018906,"gpt":0.4088705016477462,"spread":0.3143632881575571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005475978,0.0004838011,0.00500388,0.0006774621,0.00004898564,0.000005593814,0.0003308506,0.001193202,0.0001735705],"category_scores_gemma":[0.0006081489,0.00038875,0.0007453748,0.0004949637,0.0004287274,0.00001811539,0.0001196909,0.0005762002,0.00009154429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003573068,"about_ca_system_score_gemma":0.002545474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001111089,"about_ca_topic_score_gemma":0.0008747995,"domain_scores_codex":[0.9961723,0.0004801951,0.001730983,0.0005806284,0.0004286907,0.0006071822],"domain_scores_gemma":[0.996475,0.0008552603,0.0009050964,0.0008654965,0.0006904437,0.0002086933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002183264,0.0002070728,0.001858146,0.1701698,0.001114631,0.0002599603,0.00008819627,8.356334e-8,0.00005708593,0.006129534,0.0028787,0.8170184],"study_design_scores_gemma":[0.0008289391,0.0006631392,0.0000143018,0.00969235,0.001402612,0.000507458,0.000008096356,0.0001417891,0.00013681,0.00002594721,0.9863067,0.0002718046],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005704225,0.9899778,0.00007478381,0.00008016757,0.0002745189,0.004470866,0.001517426,0.00006982494,0.002964139],"genre_scores_gemma":[0.002884304,0.9913799,0.004011609,0.00003086841,0.0002122377,0.0004865278,0.0003208094,0.0001207242,0.0005530121],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9834281,"threshold_uncertainty_score":0.9998564,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1980154502","doi":"10.1001/jama.2012.144878","title":"Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis","year":2012,"lang":"en","type":"article","venue":"JAMA","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1502,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Interquartile range; Hazard ratio; Gastroenterology; Hepatocellular carcinoma; Liver transplantation; Cirrhosis; Proportional hazards model; Hepatitis C; Transplantation; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02302906564572636,"gpt":0.3113977789640037,"spread":0.2883687133182773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008002489,0.0001806388,0.000362574,0.0001040168,0.000108292,0.00005311868,0.00005507987,0.0002209588,0.00009415369],"category_scores_gemma":[0.002007976,0.0001422025,0.00003221789,0.0001825647,0.000137577,0.0004782908,0.0001061471,0.0003241491,0.0000137331],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000616796,"about_ca_system_score_gemma":0.00007800161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000621471,"about_ca_topic_score_gemma":0.0004216948,"domain_scores_codex":[0.9978063,0.0004211097,0.0002723171,0.0002894494,0.0006283122,0.0005825312],"domain_scores_gemma":[0.9983614,0.0006275972,0.0001366701,0.0002604664,0.0002017925,0.0004120372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008191145,0.00009589822,0.9878171,0.00008208662,0.0004775336,0.00001338317,0.0002347959,3.410831e-7,0.000321501,0.000006750919,0.0002047729,0.009926737],"study_design_scores_gemma":[0.003954883,0.001288685,0.9926871,0.00006675009,0.0003776425,8.949624e-7,0.00001548704,0.0001226569,0.0002806092,0.00001380141,0.001032486,0.0001590125],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978611,0.0001674144,0.00003094815,0.000836973,0.00002516127,0.0008032199,0.00007496234,0.00005905455,0.0001411158],"genre_scores_gemma":[0.9986525,0.0003087795,0.0002666971,0.0001469982,0.0001412189,0.00007122676,0.0001048723,0.00002830583,0.0002793988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009767725,"threshold_uncertainty_score":0.5798849,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1996434966","doi":"10.1056/nejmoa040842","title":"Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients","year":2004,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1235,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Ribavirin; Medicine; Internal medicine; Peginterferon alfa-2a; Gastroenterology; Hepatitis C; Placebo; Interferon alfa; Hepatitis C virus; Alpha interferon; Interferon; Virology; Immunology; Virus; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02563220288722058,"gpt":0.3223026156713883,"spread":0.2966704127841677,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000888362,0.0002229612,0.0007193686,0.0007080685,0.00005481618,0.0000142086,0.0001239734,0.0001369921,0.0002958848],"category_scores_gemma":[0.001627583,0.0001661809,0.0001223827,0.0003811228,0.0001067856,0.00020923,0.000031491,0.0006970992,0.00002713561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001571611,"about_ca_system_score_gemma":0.0009232463,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00933775,"about_ca_topic_score_gemma":0.0169671,"domain_scores_codex":[0.9976226,0.000115265,0.0008709418,0.0002111172,0.0007474278,0.0004326503],"domain_scores_gemma":[0.9983321,0.0002013142,0.0003106759,0.0002050027,0.0005014958,0.0004494329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003158566,0.0004089635,0.7528364,0.0002481908,0.0001556629,0.0003669642,0.001351213,0.0006841486,0.004618322,0.00007878814,0.007073045,0.2290197],"study_design_scores_gemma":[0.2479314,0.01786806,0.6512774,0.002874202,0.0001974231,0.0003761153,0.00001288981,0.0004932672,0.002982422,0.0006589048,0.07507491,0.0002530446],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867584,0.0006133437,0.006393368,0.004058071,0.0007907278,0.0006834967,0.00001199114,0.00002335733,0.0006672807],"genre_scores_gemma":[0.9915375,0.004111329,0.0003746404,0.0002667135,0.003357876,0.00001206673,0.00005830688,0.00004160649,0.0002399397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2447728,"threshold_uncertainty_score":0.9972591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2332630894","doi":"10.1056/nejm200012073432301","title":"Peginterferon Alfa-2a in Patients with Chronic Hepatitis C","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1226,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Nutrasource; Toronto Western Hospital; Mount Sinai Hospital","funders":"University of Alberta; Karolinska Institutet; Massachusetts General Hospital","keywords":"Medicine; Regimen; Chronic hepatitis; Gastroenterology; Interferon alfa; Peginterferon alfa-2a; Hepatitis C; Alpha interferon; Internal medicine; Interferon; Polyethylene glycol; Immunology; Virology; Ribavirin; Virus; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01213529756932176,"gpt":0.2752661131484843,"spread":0.2631308155791625,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005764994,0.0001606725,0.0005602316,0.0003508859,0.00002619282,0.000008367389,0.0001429634,0.00006532112,0.006056509],"category_scores_gemma":[0.0002071753,0.00009739501,0.00004516295,0.0002939766,0.0001219581,0.0001426049,0.00001202977,0.0006380242,0.00004830386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003048728,"about_ca_system_score_gemma":0.0004150994,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001415356,"about_ca_topic_score_gemma":0.001555009,"domain_scores_codex":[0.9979022,0.000107695,0.0005587148,0.0001491003,0.0009504608,0.0003318014],"domain_scores_gemma":[0.9988919,0.0001034193,0.000134537,0.0002069067,0.0002232515,0.0004399656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001946583,0.00009428147,0.523596,0.00002998381,0.00004810725,0.0004028172,0.0003622922,0.00001803899,0.00004778223,0.000004492737,0.004559735,0.4688899],"study_design_scores_gemma":[0.1017336,0.01297162,0.7474963,0.001678131,0.00007363757,0.0002306182,0.00001096576,0.00008423395,0.00007243882,0.00004647012,0.1354913,0.0001107573],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986272,0.0008704253,0.00005670042,0.005716718,0.0001549687,0.0002388273,0.000002350173,0.000009116643,0.006678856],"genre_scores_gemma":[0.9940962,0.001591322,0.0002035521,0.0003843752,0.00205569,0.000001557487,0.00001161163,0.00002711495,0.001628628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4687791,"threshold_uncertainty_score":0.9948521,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077467499","doi":"10.1073/pnas.202608199","title":"Genomic analysis of the host response to hepatitis C virus infection","year":2002,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1164,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Steacie Institute for Molecular Sciences","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Biology; Gene; Immune system; Virus; Hepatitis C virus; Virology; Viral replication; Gene expression; Immunology; Replicon; Hepacivirus; Genome; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.07144290811975168,"gpt":0.3557013425330536,"spread":0.2842584344133019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00195087,0.00007122693,0.00021824,0.0006687746,0.0001607937,0.00001341399,0.0004845603,0.00006696184,0.000154336],"category_scores_gemma":[0.003002596,0.00004233936,0.0001662653,0.004039293,0.0006298051,0.0001670561,0.000175093,0.0001695923,0.000006727593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001118232,"about_ca_system_score_gemma":0.00004432318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004120938,"about_ca_topic_score_gemma":0.000009678016,"domain_scores_codex":[0.9976211,0.00002543278,0.0003488718,0.000195083,0.00166305,0.0001464526],"domain_scores_gemma":[0.9989805,0.0001935718,0.0002815564,0.00001913064,0.0004700097,0.00005518689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.00004947625,0.00004203716,0.4413838,0.00002005525,0.00007536742,5.61594e-9,0.0002602907,0.00007534763,0.5565559,0.0005031889,0.0005027653,0.0005317793],"study_design_scores_gemma":[0.0001106976,0.0000862731,0.8332379,0.00005049494,0.00008550638,0.000001670576,0.00001367356,0.003116372,0.1622262,0.0002645085,0.0007708194,0.00003591345],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887364,0.00005066597,0.000001105804,0.006717249,0.00001387788,0.0002738009,0.00003549825,0.000006225886,0.004165158],"genre_scores_gemma":[0.9986525,0.0001778297,0.0002465784,0.0004124258,0.00003263429,0.00001173217,6.64735e-8,0.000003810193,0.0004624103],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3943298,"threshold_uncertainty_score":0.3594604,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2320330796","doi":"10.1056/nejmoa1512610","title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1116,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of Alberta; Toronto Liver Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Internal medicine; Gastroenterology; Sofosbuvir; Placebo; Hepatitis C virus; Cirrhosis; Genotype; Regimen; Hepatitis C; Immunology; Ribavirin; Virus; Pathology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.08606193357011044,"gpt":0.3668908907295716,"spread":0.2808289571594612,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001449586,0.00009556318,0.0003532224,0.0002151625,0.00003733768,0.00001044743,0.00003492136,0.00006429469,0.00003359116],"category_scores_gemma":[0.002088361,0.00006218989,0.00002385737,0.0001030625,0.0001115836,0.0001051966,0.00002135027,0.0002591373,0.000002373871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004685323,"about_ca_system_score_gemma":0.0002596468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002763617,"about_ca_topic_score_gemma":0.00008368248,"domain_scores_codex":[0.9989734,0.00005644002,0.0003120331,0.0001009876,0.0003936034,0.0001635164],"domain_scores_gemma":[0.9985895,0.0001985505,0.000119761,0.00009013541,0.0003647504,0.0006373469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001846182,0.00003709555,0.09001817,0.0001089208,0.00009419415,0.0001214971,0.00126146,0.00000225982,0.002195832,0.0001170667,0.03440024,0.8697971],"study_design_scores_gemma":[0.08533107,0.00822614,0.05078305,0.0003734048,0.0002482161,0.001832219,0.0001153716,0.0003318351,0.0003948191,0.001808023,0.8504468,0.0001090018],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713552,0.006690221,0.004069505,0.01474333,0.0005124543,0.000337375,0.000004364463,0.00001364124,0.002273906],"genre_scores_gemma":[0.9912449,0.002389077,0.00143119,0.0004811441,0.003954249,0.000001994221,0.000006365958,0.00001791052,0.000473207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8696881,"threshold_uncertainty_score":0.253603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2100797437","doi":"10.1056/nejmoa0806104","title":"Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1087,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Valeant Pharmaceuticals International; Vertex Pharmaceuticals; Duke Clinical Research Institute; Gilead Sciences","keywords":"Telaprevir; Ribavirin; Medicine; Virology; Hepatitis C virus; Genotype; Protease inhibitor (pharmacology); Chronic hepatitis; Hepacivirus; Virus; Boceprevir; Pegylated interferon; Immunology; Viral load; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.02947302356834185,"gpt":0.3358792846128763,"spread":0.3064062610445344,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007401105,0.0001239044,0.0004152975,0.0002281955,0.00004465002,0.0000103381,0.00005311483,0.00005797318,0.0001288371],"category_scores_gemma":[0.0003881408,0.00007246303,0.00003943214,0.0001316183,0.0000812585,0.0001054588,0.000007746321,0.0003638717,0.000003074837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000129702,"about_ca_system_score_gemma":0.0002827263,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009090346,"about_ca_topic_score_gemma":0.0001345709,"domain_scores_codex":[0.9989112,0.00004967107,0.0003328821,0.0001202546,0.0003752242,0.0002107453],"domain_scores_gemma":[0.9990156,0.0001250873,0.0001503091,0.0001244468,0.0002497534,0.0003347453],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002697113,0.00005126526,0.01677519,0.0001024978,0.00008796724,0.0001257576,0.000372018,0.0000124559,0.007649865,0.00008300479,0.006900981,0.9651419],"study_design_scores_gemma":[0.1165801,0.0677369,0.1566055,0.00229695,0.0005046604,0.003287332,0.00003421045,0.0004555448,0.001772834,0.0006637413,0.649856,0.0002062652],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9580553,0.005161029,0.009643048,0.0230891,0.0002466001,0.0005355771,0.000001615096,0.00002019035,0.003247582],"genre_scores_gemma":[0.9914866,0.002498327,0.0008047302,0.0004190369,0.004142107,0.000001624064,0.000004183117,0.00001512751,0.0006282798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9649356,"threshold_uncertainty_score":0.2954957,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120733999","doi":"10.1056/nejmoa1214854","title":"Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1082,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Sofosbuvir; Ribavirin; Internal medicine; Gastroenterology; Placebo; Hepatitis C virus; Hepatitis C; Randomized controlled trial; Clinical endpoint; Genotype; Cirrhosis; Surgery; Immunology; Virus; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04729565596916431,"gpt":0.3466537882123108,"spread":0.2993581322431465,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004279842,0.0001515717,0.0005731726,0.0003683159,0.00004236969,0.00001127337,0.00009656521,0.00007219137,0.001533021],"category_scores_gemma":[0.001054889,0.0000834949,0.00007201868,0.00017803,0.00007040158,0.0001343127,0.00001311084,0.0002211878,0.00003799323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002845526,"about_ca_system_score_gemma":0.0004304949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002222947,"about_ca_topic_score_gemma":0.0008240274,"domain_scores_codex":[0.9983526,0.00008138266,0.0006183336,0.0001321662,0.0005166347,0.0002988121],"domain_scores_gemma":[0.9984234,0.0002576675,0.0001777532,0.0001734433,0.0005099251,0.0004578326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001380993,0.0002608043,0.5330968,0.00003332461,0.00009987646,0.0000640634,0.0006797744,0.000006599464,0.0003784287,0.00002346735,0.01053432,0.4534416],"study_design_scores_gemma":[0.169029,0.02110366,0.6380767,0.000648735,0.0001894999,0.0001381,0.00007146742,0.0003963477,0.0002476818,0.0005219472,0.1694265,0.0001503645],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891713,0.0004478758,0.000598493,0.007282839,0.0003508869,0.001025377,0.000008199694,0.000009934337,0.001105137],"genre_scores_gemma":[0.988798,0.001807125,0.003717098,0.0004221966,0.002095281,0.00003162668,0.0000237599,0.00002940856,0.003075539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4532912,"threshold_uncertainty_score":0.9993797,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1979174109","doi":"10.1056/nejmoa0807650","title":"Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"European Commission; Valeant Pharmaceuticals International; Gilead Sciences; Vertex Pharmaceuticals; Merz Pharmaceuticals; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Telaprevir; Ribavirin; Medicine; Virology; Boceprevir; Hepatitis C virus; Chronic hepatitis; Genotype; Pegylated interferon; Hepacivirus; Peginterferon alfa-2a; Protease inhibitor (pharmacology); Internal medicine; Gastroenterology; Virus; Viral load; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.0431857570678463,"gpt":0.3676181674281011,"spread":0.3244324103602547,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008125893,0.0001448619,0.0005399312,0.0002474639,0.000048575,0.00001287434,0.00005904273,0.00006224693,0.0001677053],"category_scores_gemma":[0.0005104461,0.00007454327,0.00003970235,0.0001479862,0.00009999464,0.0001311325,0.000008506308,0.0003947957,0.000002313572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001344768,"about_ca_system_score_gemma":0.0003913087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008656174,"about_ca_topic_score_gemma":0.0002724316,"domain_scores_codex":[0.9987668,0.00005897972,0.0003806894,0.0001358408,0.0004267682,0.0002309185],"domain_scores_gemma":[0.998902,0.000153535,0.0001783134,0.0001361534,0.0002468698,0.0003831817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007049674,0.00006504506,0.04104974,0.0001419927,0.00009938583,0.0001643634,0.000551731,0.000006989485,0.003610871,0.00003297685,0.006595403,0.9406318],"study_design_scores_gemma":[0.1746395,0.1043029,0.08381135,0.004334843,0.000643391,0.006586094,0.00007967596,0.001210335,0.001390747,0.0002866459,0.6224608,0.0002537514],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9605532,0.002495154,0.01257683,0.02074596,0.0002448554,0.0007465756,0.000001760516,0.00002596548,0.00260974],"genre_scores_gemma":[0.9911259,0.002200685,0.0008683251,0.0004513667,0.004010767,0.000002681837,0.000003252572,0.00001799788,0.001319045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9403781,"threshold_uncertainty_score":0.3039787,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142684817","doi":"10.1038/nature02099","title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","year":2003,"lang":"en","type":"article","venue":"Nature","topic":"Hepatitis C virus research","field":"Medicine","cited_by":913,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"NS3; Hepatitis C virus; Virology; Protease inhibitor (pharmacology); Protease; Hepatitis C; Medicine; Ribavirin; Virus; Hepacivirus; Interferon; Immunology; Pharmacology; Biology; Viral load; Enzyme","retraction":null,"screen_n_in":null,"score":{"opus":0.006832773382691644,"gpt":0.292989150956293,"spread":0.2861563775736014,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002449601,0.0002472834,0.0003636654,0.0003190153,0.00007792183,0.00004463095,0.00009918529,0.0007524084,0.00008860166],"category_scores_gemma":[0.0004028672,0.0001721528,0.00003333315,0.0008946058,0.000121281,0.0002514083,0.00001549859,0.003101854,0.00004136501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001555047,"about_ca_system_score_gemma":0.0003908221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008961863,"about_ca_topic_score_gemma":0.0088129,"domain_scores_codex":[0.9979063,0.0002901975,0.0001679204,0.0004425813,0.0007045261,0.00048848],"domain_scores_gemma":[0.9989774,0.00006466054,0.00005031875,0.0004638169,0.0002065254,0.0002372688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005447042,0.0005382423,0.9714828,0.0002270418,0.00004201731,0.00231034,0.0002732738,0.000002379035,0.02031991,0.0003309824,0.000527981,0.003400355],"study_design_scores_gemma":[0.008219974,0.005596693,0.8520329,0.0009656648,0.00005497164,0.00005401294,0.00002183964,0.0001275618,0.1210186,0.00006230782,0.0113703,0.0004752091],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921699,0.0001981858,0.00006922931,0.0001313703,0.00005523253,0.001838845,0.00001857927,0.0001113915,0.005407289],"genre_scores_gemma":[0.997173,0.00003587706,0.001584096,0.0005863643,0.0001105748,0.0001718582,0.00005239093,0.00006433283,0.0002215197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1194499,"threshold_uncertainty_score":0.999198,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043193067","doi":"10.1056/nejmoa1315722","title":"Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":907,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto Liver Centre; University of Toronto","funders":"","keywords":"Dasabuvir; Ombitasvir; Ribavirin; Virology; Paritaprevir; Medicine; Hepatitis C virus; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.02277799237174971,"gpt":0.3027852026373167,"spread":0.280007210265567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006286671,0.000189432,0.0008173219,0.0002647252,0.00003634454,0.000006991967,0.00008197501,0.00005634073,0.0001527632],"category_scores_gemma":[0.0002635831,0.00008993735,0.00003913205,0.0001949703,0.0003110814,0.00008308692,0.00001163539,0.0002490292,0.000003215075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007064371,"about_ca_system_score_gemma":0.0002644175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003924964,"about_ca_topic_score_gemma":0.0001921917,"domain_scores_codex":[0.9981838,0.0001284716,0.0004667078,0.0001570654,0.000823898,0.0002400118],"domain_scores_gemma":[0.9983212,0.0003176128,0.0002706337,0.0002504455,0.0002867263,0.0005534046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005864041,0.0002578411,0.2320828,0.0001072013,0.0004132174,0.0007663803,0.001827972,0.00001267858,0.002501928,0.0001669085,0.001375826,0.7546232],"study_design_scores_gemma":[0.2728416,0.1153779,0.1202864,0.002209666,0.001014253,0.005135689,0.000407027,0.0002868945,0.003185461,0.0002299178,0.4787552,0.0002699103],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774787,0.001432374,0.001045355,0.008547019,0.00007381466,0.0002732766,0.000002805984,0.00000999911,0.01113661],"genre_scores_gemma":[0.9945973,0.001389099,0.001647033,0.0001566596,0.001407725,0.000002048924,0.000004439958,0.00002669191,0.0007690381],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7543533,"threshold_uncertainty_score":0.3667539,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2011707824","doi":"10.1056/nejm200012073432302","title":"Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":886,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Nutrasource; Heritage Medical Research Clinic; Toronto Western Hospital; University Health Network","funders":"","keywords":"Medicine; Cirrhosis; Gastroenterology; Internal medicine; Regimen; Chronic hepatitis; Interferon; Peginterferon alfa-2a; Hepatitis C; Interferon alfa; Alpha interferon; Ribavirin; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.01066154462504708,"gpt":0.2650532985136315,"spread":0.2543917538885844,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005014809,0.0001476992,0.0005140456,0.0003174445,0.00002808875,0.000009759509,0.00009188873,0.00006026623,0.002631358],"category_scores_gemma":[0.0001718045,0.00009123243,0.00002913793,0.0002256129,0.0001386864,0.0001343037,0.00001361909,0.0005013514,0.00001311285],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001872855,"about_ca_system_score_gemma":0.0002364961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001527274,"about_ca_topic_score_gemma":0.001325716,"domain_scores_codex":[0.9983277,0.00009104162,0.0004600511,0.0001490904,0.0006961317,0.0002760405],"domain_scores_gemma":[0.9990343,0.0001093613,0.0001127866,0.000157055,0.0001653146,0.0004211822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001213406,0.00005556288,0.5500195,0.0000327049,0.00004213377,0.0001972111,0.0003885961,0.000004127358,0.00004361911,0.000003213047,0.001763217,0.4462367],"study_design_scores_gemma":[0.07556515,0.01021975,0.8558935,0.001430508,0.00008005831,0.0002236619,0.00001314714,0.00007699674,0.00004908175,0.00004079854,0.05631186,0.00009548854],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897621,0.001424569,0.00003267736,0.005553441,0.0000908401,0.0002098438,0.000002373597,0.000006758691,0.002917355],"genre_scores_gemma":[0.9939783,0.003597108,0.0001909317,0.0003274146,0.001154578,0.000001527347,0.000007054405,0.00002225059,0.000720787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4461412,"threshold_uncertainty_score":0.9982803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1535549793","doi":"10.1038/90968","title":"Hepatitis C virus replication in mice with chimeric human livers","year":2001,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":877,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Saint-Luc; Université de Montréal; University of Alberta","funders":"University of Alberta","keywords":"Virology; Biology; Viral replication; Transgene; Virus; Hepatitis C virus; Chimera (genetics); Genetically modified mouse; Titer; Hepacivirus; Viral hepatitis; Hepatocyte; Immunology; Gene; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.02005823704445813,"gpt":0.3519652658982874,"spread":0.3319070288538293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004747654,0.0001879534,0.000405232,0.0004601297,0.00007724433,0.000006828232,0.0001663927,0.0002731795,0.0009040452],"category_scores_gemma":[0.0005612053,0.000135634,0.00003166385,0.001240938,0.0002227801,0.00009410444,0.00003090159,0.00125396,0.00007956235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002536776,"about_ca_system_score_gemma":0.0001012631,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008974367,"about_ca_topic_score_gemma":0.007890376,"domain_scores_codex":[0.9979306,0.00007586371,0.0003056526,0.0005126953,0.0007982763,0.0003768396],"domain_scores_gemma":[0.9987407,0.00008406871,0.00008591609,0.0006581523,0.0002020624,0.0002290947],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00049293,0.0002501361,0.853376,0.0001014622,0.00006945387,0.00147344,0.0009217152,0.000002548173,0.09132049,0.0002623166,0.01043242,0.04129709],"study_design_scores_gemma":[0.005600439,0.002082466,0.8572518,0.000830332,0.0000870858,0.0003043081,0.0001056767,0.0002685269,0.007205567,0.00008013668,0.1259214,0.0002622473],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.945357,0.00153801,0.00005111174,0.006876369,0.00008590209,0.0006642808,0.000004057902,0.00009214351,0.04533111],"genre_scores_gemma":[0.9920557,0.002181667,0.0003794201,0.002347565,0.0004421266,0.00005025683,0.0001356406,0.00003922389,0.002368416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.115489,"threshold_uncertainty_score":0.9976249,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973675889","doi":"10.1056/nejmoa1402869","title":"ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":877,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Ombitasvir; Dasabuvir; Ribavirin; Paritaprevir; Ritonavir; Medicine; Virology; Cirrhosis; Hepatitis C; Hepatitis C virus; Gastroenterology; Internal medicine; Virus; Viral load","retraction":null,"screen_n_in":null,"score":{"opus":0.0191172941550642,"gpt":0.292906241556971,"spread":0.2737889474019068,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001525464,0.000219341,0.0007863886,0.0003065158,0.00008526345,0.00002106028,0.0001299725,0.00007893347,0.0001591284],"category_scores_gemma":[0.0009624233,0.0001194342,0.00005083661,0.0002254518,0.0002851783,0.0001477602,0.00002102244,0.0004688545,0.000003927986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006261774,"about_ca_system_score_gemma":0.0002735431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005123421,"about_ca_topic_score_gemma":0.000571898,"domain_scores_codex":[0.9979279,0.0001177313,0.0005119839,0.0002216677,0.0008655694,0.0003551515],"domain_scores_gemma":[0.9976279,0.0006128001,0.0002734314,0.0002565924,0.0004876608,0.0007416315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005794437,0.0001170486,0.3684875,0.0002620541,0.0004219358,0.0003902701,0.001163788,0.00001129013,0.002082726,0.0004128753,0.01723182,0.6036243],"study_design_scores_gemma":[0.1957784,0.0467417,0.1542095,0.003106711,0.0009150187,0.004783352,0.0002058816,0.0007634599,0.001296174,0.0007897927,0.5910225,0.0003875395],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9530832,0.001067779,0.01709053,0.02256888,0.0001721762,0.0006139163,0.000008893996,0.00002533415,0.005369314],"genre_scores_gemma":[0.9877807,0.001069186,0.006530868,0.001038723,0.002754412,0.000009262728,0.00001068513,0.00004977798,0.0007564193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6032367,"threshold_uncertainty_score":0.4870386,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2289667014","doi":"10.1056/nejmoa1512612","title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver Infectious Diseases Centre; University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Medicine; Sofosbuvir; Ribavirin; Internal medicine; Gastroenterology; Hepatitis C virus; Randomized controlled trial; Hepatitis C; Confidence interval; Virology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.08687197760678626,"gpt":0.3694498656521075,"spread":0.2825778880453212,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001404087,0.00009184365,0.0003413086,0.0002076803,0.00003589339,0.000009985618,0.00003357974,0.00006183735,0.00003537708],"category_scores_gemma":[0.002071427,0.00005956623,0.00002281481,0.00009930791,0.0001073405,0.000101463,0.00002045863,0.0002536878,0.000002359001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000457455,"about_ca_system_score_gemma":0.0002523718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002760233,"about_ca_topic_score_gemma":0.00007856703,"domain_scores_codex":[0.999007,0.00005444399,0.0003016968,0.00009714128,0.0003817621,0.0001579944],"domain_scores_gemma":[0.9986307,0.0001931406,0.0001155192,0.00008685468,0.0003551973,0.0006185961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001741598,0.00003296305,0.09254989,0.0001037029,0.00008878658,0.0001147672,0.001225461,0.000002130214,0.002113501,0.0001049294,0.03186318,0.8700591],"study_design_scores_gemma":[0.07932745,0.008119795,0.05169772,0.000351422,0.0002322508,0.001697782,0.0001091169,0.0003143804,0.0003841096,0.00168003,0.8559845,0.0001014529],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9730207,0.006299587,0.003640405,0.01398102,0.0004959595,0.0003187331,0.000004154866,0.00001272416,0.002226668],"genre_scores_gemma":[0.9913818,0.002303154,0.001358696,0.0004727952,0.004000135,0.000001878948,0.00000618795,0.00001712237,0.0004581775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8699576,"threshold_uncertainty_score":0.2479842,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1984413237","doi":"10.1002/hep.22375","title":"Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection","year":2008,"lang":"en","type":"review","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":833,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Blood Services; University of Toronto; Toronto Public Health; University Health Network","funders":"","keywords":"Medicine; Meta-analysis; Internal medicine; Cirrhosis; Hepatitis C virus; Confidence interval; Stage (stratigraphy); Hepatitis C; Fibrosis; Gastroenterology; Immunology; Virus; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.08662654996355057,"gpt":0.4336265677940999,"spread":0.3470000178305493,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002695114,0.0004516932,0.002596308,0.001218137,0.00007464161,0.00001324266,0.0001579225,0.0008890639,0.0005694604],"category_scores_gemma":[0.0003254095,0.0003937783,0.0003829417,0.001096642,0.0003091582,0.0001244996,0.0001267205,0.0008942717,0.0003445644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001543681,"about_ca_system_score_gemma":0.001877965,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006868899,"about_ca_topic_score_gemma":0.004020712,"domain_scores_codex":[0.996331,0.000687421,0.001306286,0.0006241684,0.0004927653,0.0005583647],"domain_scores_gemma":[0.9981961,0.0003273216,0.0005575768,0.0006221865,0.0001489048,0.0001479397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000343918,0.00014983,0.04154647,0.01677035,0.00006893386,0.000277489,0.0000380628,0.000006437053,0.00001625391,0.00006050273,0.0009828159,0.9400485],"study_design_scores_gemma":[0.0006410751,0.00073726,0.001638178,0.01351657,0.0001027496,0.0002653779,4.397062e-7,0.002676045,0.0002729227,0.00001194515,0.9798436,0.000293806],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00744141,0.98932,0.0001520347,0.00002211739,0.000230902,0.002067189,0.00008195942,0.00007974048,0.0006046661],"genre_scores_gemma":[0.003582078,0.9942094,0.0005683943,0.000009454884,0.0001182624,0.0005603736,0.0006926844,0.0000925839,0.0001667641],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9788608,"threshold_uncertainty_score":0.9998514,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2119764771","doi":"10.1056/nejmoa0908014","title":"Telaprevir for Previously Treated Chronic HCV Infection","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":719,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Duke Clinical Research Institute; Vertex Pharmaceuticals","keywords":"Telaprevir; Ribavirin; Medicine; Gastroenterology; Internal medicine; Peginterferon alfa-2a; Boceprevir; Hepatitis C virus; Hepatitis C; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.03136662198516695,"gpt":0.3560272563528978,"spread":0.3246606343677308,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015457,0.0001453763,0.0005334928,0.0003227023,0.00005809256,0.00001052184,0.0001020736,0.0001231625,0.0008974197],"category_scores_gemma":[0.00249564,0.0000908009,0.0001194703,0.0002281585,0.0001118148,0.0001129686,0.00001390657,0.0008052122,0.00001650346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000121969,"about_ca_system_score_gemma":0.0005805561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003214152,"about_ca_topic_score_gemma":0.0005898863,"domain_scores_codex":[0.9984126,0.00006914999,0.0005680086,0.0001329217,0.0005201906,0.0002971282],"domain_scores_gemma":[0.9982293,0.000299784,0.0002437214,0.0002170108,0.0004837217,0.0005264805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008803527,0.00007801476,0.05488745,0.0001789468,0.0001429941,0.0001240028,0.0003033385,0.00000366602,0.04979188,0.00007741893,0.02675994,0.866772],"study_design_scores_gemma":[0.06298731,0.007902896,0.02026935,0.0006685911,0.0003377875,0.00126562,0.000007463577,0.0002484622,0.003601932,0.0002432595,0.9023631,0.0001041872],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783334,0.001581873,0.002018508,0.0101007,0.001181149,0.0007882299,0.000002747606,0.00003411334,0.005959338],"genre_scores_gemma":[0.9819847,0.001878181,0.0007509194,0.0002534711,0.01307739,0.000008083893,0.000012123,0.00003215236,0.002002947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8756032,"threshold_uncertainty_score":0.9826117,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2064546869","doi":"10.1016/s0140-6736(10)60934-8","title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"Hepatitis C virus research","field":"Medicine","cited_by":704,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Society of Intestinal Research","funders":"","keywords":"Boceprevir; Ribavirin; Medicine; Internal medicine; Gastroenterology; Hepatitis C virus; Clinical endpoint; Hepatitis C; NS3; Virology; Randomized controlled trial; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.04446217958729531,"gpt":0.3619008078006831,"spread":0.3174386282133878,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005694693,0.0002022829,0.0006124866,0.0001703342,0.00006298122,0.00006671817,0.0001734391,0.00008771928,0.00004978872],"category_scores_gemma":[0.0002854312,0.0001255411,0.00001494363,0.0002559991,0.0001555832,0.0004250391,0.000064188,0.000381384,0.000005086304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001470318,"about_ca_system_score_gemma":0.0001905762,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01048611,"about_ca_topic_score_gemma":0.02027038,"domain_scores_codex":[0.9982588,0.0004420156,0.0003449295,0.0003555831,0.0003049818,0.0002937242],"domain_scores_gemma":[0.9988735,0.0001201305,0.0001666088,0.0005423751,0.000149656,0.000147702],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3707853,0.008869315,0.5386528,0.00005932051,0.00005100916,0.00002283007,0.001340778,0.000005429283,0.002948197,0.00003040513,0.00001661673,0.07721797],"study_design_scores_gemma":[0.6296289,0.0157147,0.3511514,0.000183681,0.00005663888,0.00000231783,0.00001886777,0.001064811,0.001802276,0.0000144113,0.0002352098,0.0001267848],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910774,0.00001744804,0.00001353501,0.0002168657,0.00006219475,0.008340364,0.0000374957,0.00002390852,0.0002108222],"genre_scores_gemma":[0.9986765,0.0001402993,0.0003709545,0.00003820339,0.0001330967,0.0004130897,0.0001672766,0.00003223929,0.00002829847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2588436,"threshold_uncertainty_score":0.9976071,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113428683","doi":"10.1056/nejmoa1402338","title":"ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":695,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Society of Intestinal Research; University of Ottawa","funders":"","keywords":"Ombitasvir; Dasabuvir; Paritaprevir; Ribavirin; Ritonavir; Medicine; Regimen; Virology; Hepatitis C; Hepatitis C virus; Internal medicine; Gastroenterology; Virus; Viral load","retraction":null,"screen_n_in":null,"score":{"opus":0.04211623164089939,"gpt":0.3526255888485085,"spread":0.3105093572076091,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002057482,0.0001982348,0.0008347417,0.000276312,0.00007348161,0.00001778096,0.0001365009,0.00008463948,0.0002339546],"category_scores_gemma":[0.002027072,0.0001003269,0.00005059297,0.0001815111,0.0002433917,0.0001257555,0.00002468498,0.000487931,0.000005701567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000505854,"about_ca_system_score_gemma":0.0003375149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001268648,"about_ca_topic_score_gemma":0.0002346115,"domain_scores_codex":[0.998017,0.0001246699,0.0005452792,0.0001966238,0.0007780848,0.0003383797],"domain_scores_gemma":[0.9977204,0.0006672986,0.0002444685,0.000242542,0.0003842025,0.0007411147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01344761,0.0001160808,0.1222505,0.0002854952,0.0002966371,0.0003149891,0.001382551,0.000005357361,0.003286366,0.0002795901,0.02773811,0.8305967],"study_design_scores_gemma":[0.1542768,0.02262973,0.01568262,0.001555873,0.0004431355,0.002760495,0.0002135621,0.0009129901,0.0006057533,0.0005018876,0.8002124,0.000204764],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9380744,0.001377687,0.01870745,0.03010925,0.0004229154,0.0009736124,0.00000758689,0.00003735136,0.01028981],"genre_scores_gemma":[0.9851197,0.000575643,0.005583917,0.001196269,0.00458368,0.000006117632,0.000006379698,0.00004538381,0.002882935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8303919,"threshold_uncertainty_score":0.4091212,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137929296","doi":"10.1084/jem.20030239","title":"Memory CD8 <b>+</b> T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection","year":2003,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":647,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Emory University; American Liver Foundation; National Institutes of Health; National Center for Research Resources; Cancer Research Institute","keywords":"Viremia; Cytotoxic T cell; Immunology; Virology; CD8; Hepatitis C virus; Biology; Virus; Immune system; Chronic infection; Antibody; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.07220070815171706,"gpt":0.3420785781145159,"spread":0.2698778699627988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001106384,0.0001859921,0.0004764554,0.0001983045,0.000189244,0.00001167151,0.0001162455,0.00009551956,0.0007613351],"category_scores_gemma":[0.0006173333,0.00011535,0.0002094253,0.0002016846,0.0002238693,0.0001542619,0.00002293594,0.000373415,0.00002398272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004908093,"about_ca_system_score_gemma":0.0001160737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003128642,"about_ca_topic_score_gemma":0.0001283867,"domain_scores_codex":[0.9978656,0.0003212407,0.0006144985,0.0001541937,0.0007734727,0.0002709541],"domain_scores_gemma":[0.9985233,0.0001814119,0.0004442938,0.0002722437,0.0003303833,0.0002483886],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00120052,0.0002940334,0.001602805,0.00003767051,0.0002190629,0.00003900387,0.0023143,0.00001706081,0.9872084,0.000008546487,0.004619063,0.00243955],"study_design_scores_gemma":[0.00534788,0.006072671,0.002085149,0.0006024195,0.0002918574,0.0002694504,0.002557389,0.0002484909,0.9721848,0.00007942798,0.01013029,0.000130124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988106,0.00433612,0.001866301,0.001581492,0.001214012,0.001218547,0.0000118367,0.00002193224,0.001643758],"genre_scores_gemma":[0.9963183,0.001453884,0.0003639693,0.0004530069,0.0009144829,0.00004847843,0.000005502844,0.00003812104,0.0004041943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01502353,"threshold_uncertainty_score":0.8336085,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2913125611","doi":"10.1016/s0140-6736(18)32111-1","title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Hepatitis C virus research","field":"Medicine","cited_by":631,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"Agence Nationale de la Recherche; Institut National de la Santé et de la Recherche Médicale; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Cirrhosis; Gastroenterology; Hepatology; Ribavirin; Liver transplantation; Hepatitis C; Prospective cohort study; Incidence (geometry); Cohort; Cohort study; Transplantation; Hepatitis C virus; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.02935598667923823,"gpt":0.3586807757196055,"spread":0.3293247890403673,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005032736,0.0001665263,0.0008464227,0.00006034896,0.00003873884,0.00002733352,0.0001249602,0.00004792482,0.0001813129],"category_scores_gemma":[0.0001275572,0.00008766377,0.00006747377,0.0001964425,0.00007602589,0.00009449847,0.00006570839,0.0003131971,0.0002967535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004100995,"about_ca_system_score_gemma":0.0001159372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001764015,"about_ca_topic_score_gemma":0.005833885,"domain_scores_codex":[0.9982584,0.0002638552,0.0002845,0.000361075,0.0004335632,0.0003986264],"domain_scores_gemma":[0.9989411,0.0002045619,0.00007068646,0.0006600312,0.00006794997,0.00005568262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001181452,0.0009039289,0.9860634,0.00001560649,0.0003194099,0.00005198389,0.0005436009,5.798476e-7,4.896459e-7,0.000001560611,0.00004345287,0.01087455],"study_design_scores_gemma":[0.01043783,0.004096585,0.9841599,0.00007214099,0.00005373869,1.93429e-7,0.00002326247,0.00004420841,0.000006412944,0.000002778623,0.0009975765,0.0001053559],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791477,0.00002614204,5.930943e-7,0.0002049067,0.00008966279,0.003723097,0.0000303726,0.00004640744,0.01673115],"genre_scores_gemma":[0.9981674,0.00006260773,0.00003563035,0.0001399729,0.0002033626,0.000331083,0.0000116835,0.00003055774,0.001017725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01901971,"threshold_uncertainty_score":0.3814264,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967491261","doi":"10.1038/nm1698","title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","year":2007,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Viral quasispecies; Virology; Hepatitis C virus; Heterologous; Monoclonal antibody; Antibody; Virus; Biology; Neutralizing antibody; Immunology; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03141512503758569,"gpt":0.3642167841273667,"spread":0.332801659089781,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001667322,0.0004158081,0.0008588092,0.0007149607,0.0002337563,0.00002304349,0.0002900188,0.0006842522,0.000570325],"category_scores_gemma":[0.001927082,0.0003113139,0.0001555203,0.0008457477,0.000525393,0.0001621107,0.0001056975,0.002477402,0.0001490742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000291246,"about_ca_system_score_gemma":0.0001502228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001619095,"about_ca_topic_score_gemma":0.003958423,"domain_scores_codex":[0.9959686,0.0001102937,0.0006785665,0.0006194428,0.001624922,0.0009981325],"domain_scores_gemma":[0.9978051,0.0003302485,0.0001489175,0.0006887423,0.0004984608,0.0005285676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001282847,0.000771341,0.2209971,0.001677555,0.000616574,0.006916167,0.005443734,0.000002714098,0.25136,0.005338669,0.04569213,0.4599012],"study_design_scores_gemma":[0.005365968,0.002532174,0.3373541,0.002353752,0.0001654986,0.0001622302,0.0006046686,0.0001474717,0.0596245,0.00026718,0.5907127,0.0007097696],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8250021,0.0217222,0.0004031058,0.01680253,0.0009629134,0.001687302,0.00002661711,0.0004316975,0.1329615],"genre_scores_gemma":[0.9775749,0.01381806,0.0009554189,0.003328066,0.002409498,0.00003481998,0.0000880244,0.00008704085,0.001704137],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5450205,"threshold_uncertainty_score":0.9999339,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2617500612","doi":"10.1056/nejmoa1613512","title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; St. Paul's Hospital","funders":"","keywords":"Medicine; Sofosbuvir; Virology; Hepatitis C virus; Virus; Ribavirin","retraction":null,"screen_n_in":null,"score":{"opus":0.07172985422738207,"gpt":0.3896005588701361,"spread":0.317870704642754,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001662619,0.0001605176,0.0006143869,0.0002315419,0.0002152319,0.00004148623,0.0001417128,0.00009835662,0.0001534099],"category_scores_gemma":[0.0042742,0.000102211,0.0000834703,0.0000609079,0.0002082726,0.0002363702,0.00003843464,0.0003812491,0.000005676844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006715146,"about_ca_system_score_gemma":0.0002138504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007065654,"about_ca_topic_score_gemma":0.0001919434,"domain_scores_codex":[0.998502,0.00007900012,0.0005166837,0.0001602641,0.0004684533,0.0002736648],"domain_scores_gemma":[0.9980603,0.0002424838,0.0004405801,0.0003453297,0.0003788655,0.0005323769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001420803,0.00005573991,0.1556819,0.0001761092,0.0001589463,0.0001812006,0.0003678998,8.128253e-7,0.003359816,0.00005352744,0.01965589,0.8188873],"study_design_scores_gemma":[0.08643594,0.007103402,0.1843311,0.001288255,0.0005357923,0.001116997,0.00001975997,0.0002337823,0.001385116,0.0005781667,0.7168175,0.0001541263],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714913,0.002598983,0.001978832,0.01680394,0.0006045242,0.0009262991,0.000008818814,0.00002362419,0.005563626],"genre_scores_gemma":[0.9874476,0.00527609,0.0006534694,0.0002881858,0.004460278,0.000007389164,0.00001036506,0.00002901537,0.001827581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8187332,"threshold_uncertainty_score":0.5116925,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4241616429","doi":"10.1056/nejmoa1401561","title":"Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":519,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Society of Intestinal Research","funders":"","keywords":"Ombitasvir; Dasabuvir; Ribavirin; Paritaprevir; Ritonavir; Medicine; Virology; Hepatitis C virus; Virus; Viral load","retraction":null,"screen_n_in":null,"score":{"opus":0.01611634576741474,"gpt":0.2841244390193666,"spread":0.2680080932519519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001222483,0.0001851855,0.0007802359,0.0002721254,0.00003779595,0.000007228442,0.0001025913,0.00006164306,0.0001846206],"category_scores_gemma":[0.0004730585,0.0000915508,0.00003571474,0.0002298366,0.0003305094,0.00009196191,0.0000216505,0.0004361063,0.000003304967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006075322,"about_ca_system_score_gemma":0.0002592125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000308744,"about_ca_topic_score_gemma":0.0001674758,"domain_scores_codex":[0.9979175,0.0001425641,0.0005022641,0.0001658809,0.001024626,0.0002471312],"domain_scores_gemma":[0.99819,0.0003131417,0.000309483,0.0002724799,0.0003490489,0.0005657978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006980395,0.0002208673,0.3672456,0.0002091941,0.0005515139,0.000979599,0.00165067,0.00001550267,0.003048855,0.0002780724,0.004975574,0.6138442],"study_design_scores_gemma":[0.3030507,0.08878259,0.2454505,0.006429146,0.001446645,0.006042764,0.000604454,0.0003085565,0.004785645,0.0005375256,0.3421526,0.0004087864],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742843,0.001231177,0.001215276,0.008763378,0.00007674916,0.0002679559,0.000002729041,0.00001056211,0.01414785],"genre_scores_gemma":[0.9948201,0.0007939271,0.002291304,0.0002774207,0.001108925,0.000001600597,0.000004496821,0.00002757395,0.0006746876],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6134354,"threshold_uncertainty_score":0.3733333,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115399503","doi":"10.1002/hep.26431","title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","year":2013,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":502,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"AIDS Vancouver; University of British Columbia","funders":"National Institute on Drug Abuse; Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement; Economic and Social Research Council; Medical Research Council; Canadian Institutes of Health Research; National Institute for Health and Care Research; National Institutes of Health; National Health and Medical Research Council; Cancer Research UK; Michael Smith Health Research BC; United Kingdom Clinical Research Collaboration; University of New South Wales; British Heart Foundation; Wellcome Trust; Australian Government; Gilead Sciences","keywords":"Medicine; Virology; Intensive care medicine; Scale (ratio)","retraction":null,"screen_n_in":null,"score":{"opus":0.06105519014898377,"gpt":0.357118141643203,"spread":0.2960629514942193,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003563467,0.0002522551,0.0008809787,0.0002725744,0.0001130841,0.00002811121,0.0001308953,0.0001755043,0.0001204739],"category_scores_gemma":[0.0001505071,0.0001755444,0.0002432322,0.0003054123,0.0001010466,0.000168139,0.00003063511,0.0001285758,0.00003498447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003899788,"about_ca_system_score_gemma":0.0001436296,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.09072194,"about_ca_topic_score_gemma":0.08082249,"domain_scores_codex":[0.9977176,0.0004547951,0.0005987774,0.0004123206,0.000267599,0.0005489499],"domain_scores_gemma":[0.9987379,0.0004600715,0.0001430182,0.0004511853,0.0001302098,0.00007758218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0001335527,0.0005100127,0.9060469,0.00009535837,0.0001234261,0.00003273088,0.01151358,0.0000307193,0.001698527,0.00001894994,0.0001573694,0.07963894],"study_design_scores_gemma":[0.01680597,0.01263516,0.3033146,0.0008910885,0.0005591587,0.00006191141,0.004908312,0.609163,0.04286259,0.001050999,0.006781314,0.0009658599],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916088,0.0002478769,0.0007962452,0.0004100915,0.0001019229,0.002965827,0.00003686191,0.00004084416,0.003791509],"genre_scores_gemma":[0.9942916,0.002487921,0.0005409791,0.00008739965,0.00006634954,0.00175334,0.0001162052,0.00003931155,0.0006168646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6091323,"threshold_uncertainty_score":0.9359501,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4232907328","doi":"10.1056/nejmoa066403","title":"Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":490,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Valeant Pharmaceuticals International; Gilead Sciences; Vertex Pharmaceuticals; GlaxoSmithKline","keywords":"Medicine; Ribavirin; Regimen; Internal medicine; Gastroenterology; Peginterferon alfa-2a; Hepatitis C virus; Liter; Odds ratio; Hepatitis C; Randomized controlled trial; Confidence interval; Surgery; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.07762475862658684,"gpt":0.3874304482813447,"spread":0.3098056896547579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002985018,0.0001703099,0.0006528,0.000536535,0.00003820314,0.00001094404,0.0001337966,0.0001164441,0.0008543749],"category_scores_gemma":[0.00259274,0.00009290002,0.00005077248,0.0002618381,0.0001287427,0.00009721422,0.00003279367,0.0006073804,0.000006513164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000189738,"about_ca_system_score_gemma":0.0004228244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003784693,"about_ca_topic_score_gemma":0.003764057,"domain_scores_codex":[0.9979895,0.00007055699,0.0007593502,0.0001744138,0.0005842682,0.0004218866],"domain_scores_gemma":[0.9979603,0.0008353745,0.0001840157,0.0001681374,0.000253546,0.0005986717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02823876,0.0001217264,0.03005349,0.000216079,0.0001073908,0.002261875,0.001547584,0.00000160733,0.004720869,0.00005658851,0.03650124,0.8961728],"study_design_scores_gemma":[0.1224522,0.01729196,0.02896779,0.001791451,0.0001770116,0.002716226,0.0006138431,0.0001343181,0.00154655,0.0003841481,0.8237312,0.0001932407],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9566853,0.003545029,0.007496555,0.02487407,0.001054083,0.0007673825,0.000006671975,0.00001814062,0.005552762],"genre_scores_gemma":[0.9828215,0.001945091,0.001934638,0.001005087,0.00484123,0.000002551279,0.000006560642,0.00003707688,0.00740632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8959795,"threshold_uncertainty_score":0.9354806,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2017232326","doi":"10.1111/jvh.12248","title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","year":2014,"lang":"en","type":"article","venue":"Journal of Viral Hepatitis","topic":"Hepatitis C virus research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Health Sciences Centre; Capital District Health Authority; University Health Network; Dalhousie University; University of Toronto; Western University; University of Manitoba; BC Centre for Disease Control; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Université de Montréal; University of Calgary","funders":"National Institute for Health and Care Research; Gilead Sciences; Bristol-Myers Squibb","keywords":"Hepatitis C virus; Medicine; Liver disease; Hepatitis C; Disease; Disease burden; Population; Immunology; Virology; Intensive care medicine; Internal medicine; Virus; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.01213417593643083,"gpt":0.2871597916718016,"spread":0.2750256157353707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004152154,0.0002077208,0.0004809719,0.0001658946,0.0001839351,0.00006109236,0.0001076596,0.00007876813,0.00008211584],"category_scores_gemma":[0.000108772,0.0001174211,0.0001645263,0.0001785016,0.0002281481,0.0002337455,0.00003895464,0.0002753017,0.000008368977],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002254624,"about_ca_system_score_gemma":0.0002553076,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01199589,"about_ca_topic_score_gemma":0.003107262,"domain_scores_codex":[0.9978859,0.0002771113,0.0005604863,0.0001765003,0.0007953206,0.0003046998],"domain_scores_gemma":[0.9983394,0.0002007483,0.0003833903,0.0003279692,0.0003047549,0.0004437238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001050844,0.0002024144,0.6763595,0.00009774226,0.0002907819,0.0002126012,0.0003674441,0.00003835346,0.0002732808,0.0005927347,0.001477072,0.3190372],"study_design_scores_gemma":[0.002579826,0.006988263,0.6435147,0.0002762006,0.0002848818,0.0001393502,0.00001867948,0.001786732,0.00112462,0.0005232475,0.3426083,0.0001551632],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988767,0.00215568,0.0002622372,0.006911437,0.0002425385,0.0004549806,0.00003509973,0.00001416644,0.001156878],"genre_scores_gemma":[0.9488542,0.04847855,0.000292469,0.0000645371,0.001915263,0.00002224661,0.000007131476,0.00002997323,0.000335633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3411312,"threshold_uncertainty_score":0.9945833,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2063859957","doi":"10.1002/hep.21159","title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy","year":2006,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Ribavirin; Medicine; Internal medicine; Gastroenterology; Hepatitis C virus; Peginterferon alfa-2a; Genotype; Hepatitis C; Randomized controlled trial; Immunology; Virus; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.03455473015635417,"gpt":0.3302288139729816,"spread":0.2956740838166275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003654172,0.0001645433,0.000407396,0.0008499525,0.00006706192,0.00001915792,0.0002070631,0.0001853211,0.000283648],"category_scores_gemma":[0.0002333469,0.0001580364,0.00008703835,0.0006379462,0.0001073039,0.00008681186,0.0000797118,0.0002389482,0.0006348437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001710845,"about_ca_system_score_gemma":0.0001143451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270847,"about_ca_topic_score_gemma":0.0002013441,"domain_scores_codex":[0.9978976,0.0002256087,0.0006088704,0.0004050407,0.0004211683,0.0004416598],"domain_scores_gemma":[0.9987305,0.0001054559,0.0001450962,0.0005355846,0.0003491002,0.0001342658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001291639,0.0002601559,0.9185106,0.00003511794,0.0000338924,0.00002918234,0.0003106431,0.000001770621,0.05456785,0.0007713014,0.003762549,0.02042537],"study_design_scores_gemma":[0.002012347,0.001406131,0.8914698,0.00005082323,0.00002230248,0.000006410472,0.00001853823,0.0002798399,0.04297734,0.0002213787,0.06134315,0.0001919121],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992941,0.0001536832,0.0004189976,0.0008211981,0.0003548896,0.0006911285,0.00002814417,0.00005699498,0.00453396],"genre_scores_gemma":[0.9958467,0.00006412742,0.0002443558,0.0002198252,0.00009947204,0.00006062404,0.00007674075,0.00004307124,0.003345091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0575806,"threshold_uncertainty_score":0.8159842,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2332403844","doi":"10.1056/nejmoa1501315","title":"Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":467,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto; Ottawa Hospital; University of Ottawa","funders":"National Center for Research Resources; National Institute of Allergy and Infectious Diseases; Gilead Sciences","keywords":"Medicine; Ledipasvir; Sofosbuvir; Internal medicine; Adverse effect; Efavirenz; Gastroenterology; Hepatitis C virus; Emtricitabine; Regimen; Hepatitis C; Raltegravir; Cirrhosis; Viral load; Virology; Human immunodeficiency virus (HIV); Ribavirin; Virus; Antiretroviral therapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03986833411161615,"gpt":0.3168818124856223,"spread":0.2770134783740061,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001107592,0.0001238053,0.0005052126,0.000340301,0.00001997183,0.000007411934,0.00006878636,0.0000608932,0.00004582411],"category_scores_gemma":[0.001922032,0.00007208379,0.00002369429,0.000183098,0.0001167118,0.0001097759,0.00001737149,0.0003513253,0.000003601665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009274851,"about_ca_system_score_gemma":0.0004269342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000117217,"about_ca_topic_score_gemma":0.0001226138,"domain_scores_codex":[0.9984685,0.00007499594,0.0004274368,0.0001176487,0.0006712646,0.0002402248],"domain_scores_gemma":[0.9982531,0.0002362835,0.0001596142,0.0001149289,0.0005917935,0.000644289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.00574333,0.0001386776,0.8084422,0.000067334,0.00007101263,0.0002063299,0.001324882,0.000006712624,0.0001207817,0.00003346185,0.02490862,0.1589366],"study_design_scores_gemma":[0.372292,0.02190979,0.3708563,0.001231566,0.0001827724,0.0003664716,0.0001977419,0.000266892,0.0001358461,0.0003973401,0.231998,0.0001653169],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894651,0.0004587942,0.0008394238,0.006357458,0.000173779,0.0004037666,0.000004323451,0.000008133741,0.0022892],"genre_scores_gemma":[0.9963803,0.0001241656,0.001214161,0.0003817997,0.001441606,0.000003319152,0.00001419167,0.00002189945,0.0004186122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.437586,"threshold_uncertainty_score":0.2939492,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105764241","doi":"10.1053/j.gastro.2005.01.059","title":"Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection","year":2005,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":453,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Chronic hepatitis; Virology; Medicine; Gene expression; Viral infection; Gene; Viral hepatitis; Immunology; Chronic infection; Internal medicine; Biology; Virus; Immune system; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02163980192931659,"gpt":0.3119134031495772,"spread":0.2902736012202606,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001683761,0.0001609179,0.0003838868,0.0004530828,0.00003350307,0.000006532805,0.00004384864,0.00009795249,0.0001321006],"category_scores_gemma":[0.00006759995,0.0001396955,0.00006422176,0.00009642745,0.0001925557,0.0001113116,0.00004689448,0.0001210579,0.00001278936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000515937,"about_ca_system_score_gemma":0.00006880465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001796373,"about_ca_topic_score_gemma":0.01024968,"domain_scores_codex":[0.9984839,0.0002783176,0.0003442835,0.00029642,0.0001804003,0.000416702],"domain_scores_gemma":[0.9994639,0.00006660043,0.00007541264,0.0002320714,0.00003899476,0.0001230523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002044089,0.0004149677,0.8820111,0.00005265629,0.00003444271,0.00006064433,0.0005247021,0.00004648942,0.09338262,0.000004773743,0.0000533569,0.02137017],"study_design_scores_gemma":[0.005306664,0.009587972,0.9318861,0.0000899511,0.00004020996,0.00008108648,0.00002434408,0.003174698,0.04900791,0.00002352407,0.000705584,0.00007193253],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976573,0.0002654119,0.0004291833,0.001040893,0.00005432613,0.0004256422,0.00001094923,0.00002179167,0.00009451347],"genre_scores_gemma":[0.9965949,0.002071555,0.0008918309,0.0001088554,0.00008170073,0.00007402376,0.00003248335,0.0000205591,0.0001241079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04987504,"threshold_uncertainty_score":0.5719563,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2277396963","doi":"10.1016/s1473-3099(16)00052-9","title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"Hepatitis C virus research","field":"Medicine","cited_by":446,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"Astellas Pharma; Alnylam Pharmaceuticals; Gilead Sciences; Cilag; GlaxoSmithKline","keywords":"Sofosbuvir; Ribavirin; Ledipasvir; Medicine; Hepatitis C virus; Open label; Genotype; Internal medicine; Hepatitis C; Virology; Clinical trial; Virus; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.03944632335243386,"gpt":0.343084737303476,"spread":0.3036384139510421,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002922927,0.0003077215,0.0007036312,0.0001653795,0.000239491,0.000132011,0.0001528598,0.00007289738,0.0002520035],"category_scores_gemma":[0.001503998,0.0001601013,0.0000393518,0.0003133764,0.000332963,0.0005294939,0.0002412173,0.0002140804,0.00003643925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002584178,"about_ca_system_score_gemma":0.0003282503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002263054,"about_ca_topic_score_gemma":0.006613666,"domain_scores_codex":[0.9977558,0.0003970581,0.0003555149,0.0005162736,0.0004411419,0.0005342533],"domain_scores_gemma":[0.9981,0.0006269222,0.0001479171,0.0004982417,0.0001637508,0.0004632133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3454421,0.001589454,0.55989,0.000110733,0.0001118243,0.00008701929,0.00008323525,0.000003061572,0.00006190064,0.00001748416,0.0002951339,0.09230806],"study_design_scores_gemma":[0.5109402,0.002503584,0.4832252,0.0002946814,0.0002240564,0.00000406725,0.000002412138,0.0002170378,0.00002458405,0.0000576239,0.002284376,0.0002222021],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926514,0.000770728,0.0001000232,0.0002537703,0.000131548,0.005353727,0.0003669083,0.0001300869,0.0002417964],"genre_scores_gemma":[0.9876868,0.01045425,0.00003712574,0.0004124661,0.0002751118,0.0008035385,0.00005114578,0.00005299956,0.0002265615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1654982,"threshold_uncertainty_score":0.6528741,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2788216918","doi":"10.1056/nejmoa1702417","title":"Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":437,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; Toronto Liver Centre; University of Toronto","funders":"AbbVie","keywords":"Genotype; Medicine; Virology; Biology; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.09091054521479569,"gpt":0.3987710325008429,"spread":0.3078604872860472,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001620146,0.0001576569,0.000602545,0.0005121665,0.00005633752,0.00001103507,0.0001227557,0.0001141289,0.002680727],"category_scores_gemma":[0.003443728,0.00008543317,0.00007084562,0.0003860196,0.0001543483,0.000141995,0.00002595806,0.0004676036,0.00003163936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001712982,"about_ca_system_score_gemma":0.0007096577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006416784,"about_ca_topic_score_gemma":0.003619056,"domain_scores_codex":[0.9980398,0.0001253787,0.0007243062,0.0001602481,0.000611369,0.0003388557],"domain_scores_gemma":[0.998306,0.0004319308,0.0002270831,0.0001942881,0.0004164402,0.0004241939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01381739,0.0001613404,0.06709184,0.000198,0.0001302815,0.0003689842,0.001244026,0.00000251416,0.005977594,0.00003407346,0.07210191,0.838872],"study_design_scores_gemma":[0.08197269,0.02210507,0.04078721,0.001411725,0.0001797049,0.001030257,0.00006271889,0.0002787349,0.001569424,0.0002840408,0.8501846,0.0001337962],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9581413,0.001424848,0.007475337,0.01940119,0.002379435,0.00128334,0.000008989074,0.00003800932,0.009847503],"genre_scores_gemma":[0.9752209,0.002218163,0.001811668,0.001124517,0.01509585,0.000007895649,0.00001007879,0.00003981345,0.004471086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8387383,"threshold_uncertainty_score":0.9982309,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144150348","doi":"10.1111/j.1537-2995.2004.04215.x","title":"A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors","year":2005,"lang":"en","type":"article","venue":"Transfusion","topic":"Hepatitis C virus research","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute","keywords":"Nat; Residual risk; Virology; Window period; Seroconversion; Incidence (geometry); Medicine; Infectivity; Human immunodeficiency virus (HIV); Hepatitis C virus; Biology; Immunology; Antibody; Virus; Internal medicine; Serology; Mathematics; Statistics","retraction":null,"screen_n_in":null,"score":{"opus":0.06827126090707379,"gpt":0.3775527536802215,"spread":0.3092814927731477,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004221081,0.0002110494,0.0005485254,0.000541103,0.00009756796,0.000006433631,0.00008674747,0.0002204069,0.0003477476],"category_scores_gemma":[0.0002212828,0.00019415,0.0002781273,0.0007459662,0.00009340618,0.0001268103,0.000004497578,0.0003194277,0.000002995804],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008243735,"about_ca_system_score_gemma":0.000368052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005858438,"about_ca_topic_score_gemma":0.002763964,"domain_scores_codex":[0.9979837,0.0001400704,0.0007986458,0.0002935842,0.0004963452,0.0002876322],"domain_scores_gemma":[0.9986022,0.0003957054,0.000156198,0.0002837045,0.0004007306,0.0001614473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001861722,0.0006847407,0.01037201,0.0005885187,0.00005631634,8.417758e-7,0.0004079483,0.01010493,0.5713749,0.000024336,0.000022078,0.4045016],"study_design_scores_gemma":[0.007051358,0.004803428,0.0282168,0.000624661,0.00018739,0.000002793621,0.00003450605,0.178826,0.7797689,0.0000658808,0.0002643065,0.0001539117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7411421,0.00003550818,0.256459,0.0001883574,0.00007025394,0.001321888,0.00005538247,0.00005338575,0.0006741447],"genre_scores_gemma":[0.9874646,0.0003520238,0.01189644,0.0000238728,0.00008297213,0.00005090459,0.00004885259,0.00004141288,0.00003889199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4043477,"threshold_uncertainty_score":0.8856244,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157650174","doi":"10.1371/journal.ppat.1003330","title":"IL-1β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease","year":2013,"lang":"en","type":"article","venue":"PLoS Pathogens","topic":"Hepatitis C virus research","field":"Medicine","cited_by":411,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute on Drug Abuse; National Institutes of Health","keywords":"Inflammasome; Inflammation; Immunology; Liver disease; Hepatitis C; Proinflammatory cytokine; Biology; Hepatitis C virus; Chemokine; Cirrhosis; Medicine; Virus; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01735176931192587,"gpt":0.2495714428141448,"spread":0.2322196735022189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002130322,0.0002739979,0.0002847944,0.0001160277,0.0003327146,0.0001339232,0.00008556186,0.0001646902,0.0003531452],"category_scores_gemma":[0.0008265915,0.0001854244,0.0000606903,0.000375894,0.0002700991,0.0006782988,0.00008336989,0.0005427218,0.0004164724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001497896,"about_ca_system_score_gemma":0.00014106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003656725,"about_ca_topic_score_gemma":0.0009246842,"domain_scores_codex":[0.99777,0.0002629381,0.0003485104,0.0004880966,0.0007130058,0.0004174102],"domain_scores_gemma":[0.9984598,0.0001045769,0.0001419899,0.0005516852,0.0004132239,0.0003287806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001854783,0.0002966199,0.6635863,0.0006487219,0.000220124,0.0001510424,0.001605513,0.00003448426,0.2941907,0.00007039159,0.003224988,0.0357857],"study_design_scores_gemma":[0.001537761,0.0009743574,0.8993224,0.0004946974,0.000587564,0.00007977243,0.00006801848,0.007313843,0.07928178,0.0006083533,0.009124089,0.0006073721],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925238,0.0004803255,0.0003020935,0.003592351,0.00008509629,0.002386464,0.00008595892,0.0001631072,0.0003808216],"genre_scores_gemma":[0.9898838,0.007094884,0.0004783219,0.0002668066,0.0004619962,0.000781636,0.0001440145,0.00006726488,0.0008212977],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2357361,"threshold_uncertainty_score":0.7561389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1504384931","doi":"10.1111/j.1478-3231.2011.02539.x","title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","year":2011,"lang":"en","type":"review","venue":"Liver International","topic":"Hepatitis C virus research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Ottawa","funders":"","keywords":"Epidemiology; Transmission (telecommunications); Public health; Medicine; Environmental health; Demography; Hepatitis C virus; Hepatitis C; Distribution (mathematics); Virology; Virus; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1080727197321746,"gpt":0.3909897333467008,"spread":0.2829170136145262,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009304,0.0002385948,0.002793327,0.0002757343,0.00001060546,0.000003455797,0.0003301521,0.0001297708,0.0006019968],"category_scores_gemma":[0.006759063,0.0001833593,0.0001473726,0.000286843,0.00008169022,0.00004213745,0.0001803571,0.0004251317,0.00006760428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003506599,"about_ca_system_score_gemma":0.001383754,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.7340784,"about_ca_topic_score_gemma":0.4905338,"domain_scores_codex":[0.9968224,0.0007580371,0.001503913,0.0003278156,0.0003696653,0.0002182344],"domain_scores_gemma":[0.997721,0.0008430846,0.000559863,0.0003412492,0.0004058916,0.0001288695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.000003666375,0.00003272448,0.001821579,0.9477418,0.0003565665,0.0002711863,0.00001126545,4.58936e-9,3.601823e-8,0.00108775,0.002652385,0.04602103],"study_design_scores_gemma":[0.00008980629,0.00002993109,0.0003208714,0.580011,0.0003495761,0.000145026,5.394354e-7,0.00001277108,1.155855e-7,0.000004375691,0.418943,0.00009298157],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000008602563,0.991726,0.0000068721,0.00005977569,0.0001989305,0.001369027,0.0003027256,0.000006537656,0.006321492],"genre_scores_gemma":[0.000006412537,0.9971017,0.0001614472,0.0008637102,0.00006203728,0.0001899866,0.000205568,0.00003123812,0.00137791],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4162906,"threshold_uncertainty_score":0.8091718,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1992668008","doi":"10.1097/qad.0b013e32830e6d51","title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","year":2008,"lang":"en","type":"review","venue":"AIDS","topic":"Hepatitis C virus research","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Blood Services; University of Toronto; University Health Network","funders":"","keywords":"Internal medicine; Hepatitis C virus; Medicine; Cirrhosis; Meta-analysis; Hepatitis C; Natural history; Confidence interval; Immunology; Gastroenterology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.07866858478001787,"gpt":0.3772204304828989,"spread":0.2985518457028811,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001536008,0.0004405842,0.005271551,0.001644498,0.00002696697,0.000008614573,0.0003105982,0.0003189286,0.0002068503],"category_scores_gemma":[0.0007595981,0.0002110073,0.00290573,0.002784677,0.0007427417,0.000150345,0.00009127011,0.00139174,0.00000315711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007001391,"about_ca_system_score_gemma":0.001082377,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.08570907,"about_ca_topic_score_gemma":0.001834669,"domain_scores_codex":[0.9940881,0.003043841,0.001306656,0.0003735973,0.0008784124,0.0003094652],"domain_scores_gemma":[0.9963371,0.001629073,0.0009927424,0.0007463541,0.0002403812,0.00005438818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004464728,0.0007740742,0.446235,0.002355099,0.1233499,0.0000601776,0.005694545,0.000009099531,0.00006769552,0.00008018157,0.0008226031,0.4201051],"study_design_scores_gemma":[0.008993727,0.00436799,0.7869524,0.002183232,0.1447418,0.00009907675,0.00004550559,0.0002444789,0.0001609917,0.00005756638,0.05125976,0.0008935562],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2036405,0.7940973,0.00000342578,0.00002343565,0.0000293561,0.001494214,0.0003358842,0.000007783855,0.0003681019],"genre_scores_gemma":[0.3413448,0.6582411,0.00002444429,0.00001796476,0.00001979053,0.000117689,0.0001447295,0.00002478549,0.0000646869],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4192116,"threshold_uncertainty_score":0.9203793,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2965258952","doi":"10.1053/j.gastro.2019.07.033","title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores","year":2019,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":399,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; AbbVie; Valeant Pharmaceuticals International; Gilead Sciences; U.S. Department of Veterans Affairs","keywords":"Hepatocellular carcinoma; Medicine; Internal medicine; Cirrhosis; Hazard ratio; Gastroenterology; Hepatitis C virus; Incidence (geometry); Hepatitis C; Confidence interval; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.01012677668640093,"gpt":0.2435122174435218,"spread":0.2333854407571208,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003398458,0.0001866946,0.0004138338,0.0004064401,0.00002667425,0.00001283048,0.0001493249,0.0001052344,0.001258802],"category_scores_gemma":[0.0002537753,0.0001552743,0.00007020359,0.0001933061,0.00006463554,0.00006969084,0.0000723402,0.0002069439,0.0002405301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001999845,"about_ca_system_score_gemma":0.00009387705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001359331,"about_ca_topic_score_gemma":0.001135336,"domain_scores_codex":[0.9980405,0.000223665,0.0003204046,0.0005006732,0.0003291566,0.0005855876],"domain_scores_gemma":[0.9988582,0.00009243694,0.00008894088,0.000482135,0.0002099777,0.0002683304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02692522,0.0001918228,0.9699268,0.00006957935,0.00005798711,0.00003361398,0.0002209752,0.000006413165,0.00009105635,8.466095e-7,0.0009488053,0.001526905],"study_design_scores_gemma":[0.009248053,0.006390285,0.9817718,0.00006639326,0.00006002808,0.000002964608,0.0000135026,0.001092287,0.00006951828,0.000002782705,0.001191647,0.00009073902],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967961,0.0000130502,0.0003666152,0.0005073572,0.00009682572,0.00194228,0.0002421134,0.00002455728,0.00001109937],"genre_scores_gemma":[0.9962353,0.000007945134,0.0016581,0.0009646949,0.00006583441,0.0004174419,0.0003634371,0.00004778814,0.0002395259],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01767717,"threshold_uncertainty_score":0.9996542,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2761085897","doi":"10.1056/nejmoa1704053","title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Hepatitis C virus research","field":"Medicine","cited_by":398,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Kidney disease; Disease; Internal medicine; Hepatitis C virus; Chronic hepatitis; Chronic infection; Chronic renal disease; Gastroenterology; Immunology; Virus; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.01644966209363162,"gpt":0.2971050086157481,"spread":0.2806553465221165,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007106778,0.0001266768,0.0004487995,0.000190807,0.00008128975,0.00002550241,0.0001040464,0.00004760558,0.0001158105],"category_scores_gemma":[0.0004433013,0.00007190638,0.00001784113,0.00005015084,0.0002091254,0.0001830163,0.00005552125,0.0004028325,0.000001245661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005527703,"about_ca_system_score_gemma":0.000144232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002701051,"about_ca_topic_score_gemma":0.000165722,"domain_scores_codex":[0.9986295,0.00006448862,0.0003498517,0.0001326525,0.0006188814,0.000204603],"domain_scores_gemma":[0.9988664,0.00007886666,0.0002401114,0.000214288,0.0001421428,0.0004582113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001398253,0.00006113994,0.7410758,0.00004608465,0.00004497672,0.0002117337,0.0004148775,5.005049e-7,0.00007123852,0.000006392789,0.001713621,0.2549554],"study_design_scores_gemma":[0.08663465,0.005243259,0.890949,0.001270334,0.0000694499,0.0002692266,0.00003297001,0.00001778396,0.00002356913,0.00007360728,0.01534635,0.00006982508],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909291,0.0008190362,0.00001989277,0.006211135,0.00007929838,0.000224913,0.000002551287,0.000002964013,0.001711078],"genre_scores_gemma":[0.9974843,0.00101626,0.0003501081,0.0002174703,0.0007012901,9.21425e-7,0.000003217213,0.00001298729,0.0002134377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2548856,"threshold_uncertainty_score":0.2932257,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1998416778","doi":"10.1002/hep.22694","title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy","year":2008,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":397,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Liver Center, Saint Louis University; Valeant Pharmaceuticals International; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences; National Institutes of Health; American Association for the Study of Liver Diseases; Saint Louis University; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Medicine; Cirrhosis; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Liver biopsy; Fibrosis; Biopsy; Cohort; Stage (stratigraphy); Hepatitis C","retraction":null,"screen_n_in":null,"score":{"opus":0.08691244072870742,"gpt":0.3862344682910515,"spread":0.2993220275623441,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003109716,0.0002187312,0.0008322276,0.0001392786,0.00009879095,0.000006626681,0.0001534444,0.0004989034,0.001250742],"category_scores_gemma":[0.0005885562,0.0001565158,0.0001612548,0.0001315647,0.001342098,0.00005078698,0.0001409391,0.0005532214,0.000328158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004907778,"about_ca_system_score_gemma":0.0001534719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001706938,"about_ca_topic_score_gemma":0.00004043116,"domain_scores_codex":[0.9978675,0.0002890703,0.0005256403,0.0005570546,0.0002433672,0.0005174309],"domain_scores_gemma":[0.9985937,0.00044778,0.00007665496,0.0004790215,0.0001032806,0.0002995461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005551641,0.0002476469,0.9790193,0.00001480057,0.00006976645,0.001660568,0.00005729568,6.237636e-9,0.000294027,0.00005303479,0.007716259,0.01031206],"study_design_scores_gemma":[0.002310257,0.0006462611,0.831619,0.000005796855,0.00001954361,0.0004901316,0.00000737592,0.00008696153,0.0003633806,0.0001603784,0.1641136,0.0001773672],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986696,0.003844885,0.00003342378,0.004967627,0.0001934409,0.0003545651,0.000007989185,0.0001153773,0.003786671],"genre_scores_gemma":[0.9796685,0.01149409,0.0009093345,0.007111039,0.0000936125,0.00009596079,0.00001253042,0.00002481033,0.0005901376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1563973,"threshold_uncertainty_score":0.9996622,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106110144","doi":"10.1002/hep.26639","title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","year":2013,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; Rijksinstituut voor Volksgezondheid en Milieu; National Health and Medical Research Council; Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health; Blood Systems Research Institute; Australian Government; Gilead Sciences","keywords":"Genotype; Hepatitis C virus; Medicine; Interleukin 28B; Coinfection; Internal medicine; Clearance rate; Immunology; Clearance; Confidence interval; Hazard ratio; Hepatitis C; Hepacivirus; Gastroenterology; Virology; Human immunodeficiency virus (HIV); Virus; Biology; Ribavirin","retraction":null,"screen_n_in":null,"score":{"opus":0.009370186379863907,"gpt":0.277284007166921,"spread":0.2679138207870571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001698895,0.0001562649,0.0004620281,0.0001026291,0.0001080105,0.00001009419,0.00009825489,0.0001880239,0.000112777],"category_scores_gemma":[0.0002383381,0.0001175855,0.00007154194,0.0001669011,0.0003755295,0.00005480878,0.00007761259,0.0002912735,0.0001624871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006074986,"about_ca_system_score_gemma":0.00009547669,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01250714,"about_ca_topic_score_gemma":0.001972609,"domain_scores_codex":[0.9985408,0.0002211821,0.0003361617,0.0002616313,0.000280791,0.0003594439],"domain_scores_gemma":[0.9986947,0.0004729302,0.0001293458,0.0004040289,0.0001839454,0.0001150206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007685439,0.0001724876,0.8378169,0.0005796878,0.0003793583,0.0008477611,0.0003299345,0.000001166519,0.06700737,0.0007780691,0.0005736916,0.09074503],"study_design_scores_gemma":[0.001847406,0.00494543,0.8718933,0.0002042887,0.0001845522,0.0008963519,0.000009094005,0.002348025,0.1123867,0.0004145076,0.004647794,0.000222514],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964181,0.0007131664,0.00004509705,0.0001920973,0.0002375033,0.000783846,0.00001211528,0.00003286955,0.001565264],"genre_scores_gemma":[0.9886776,0.01030767,0.0001423598,0.0001775314,0.00004696452,0.00006863556,0.000007337081,0.00002914015,0.0005427892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09052251,"threshold_uncertainty_score":0.9940687,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139773897","doi":"10.1053/j.gastro.2015.08.035","title":"Extrahepatic Morbidity and Mortality of Chronic Hepatitis C","year":2015,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto Liver Centre; University of Toronto","funders":"","keywords":"Medicine; Cryoglobulinemia; Ribavirin; Hepatitis C virus; Hepatitis C; Immunology; Insulin resistance; Internal medicine; Diabetes mellitus; Gastroenterology; Alpha interferon; Interferon; Insulin; Virus; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.1259670014629681,"gpt":0.4184506822662299,"spread":0.2924836808032618,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006568579,0.0003818136,0.00296176,0.000305779,0.00002579571,0.000008620442,0.0002145906,0.0003587253,0.0002764251],"category_scores_gemma":[0.0001961451,0.0003215837,0.0003153313,0.0001573836,0.0004799196,0.00004743297,0.0002650988,0.0006654089,0.00006599616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003684929,"about_ca_system_score_gemma":0.0007066003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001181224,"about_ca_topic_score_gemma":0.001941169,"domain_scores_codex":[0.9970004,0.0005493367,0.0008813855,0.0005241311,0.0004502268,0.0005945091],"domain_scores_gemma":[0.9982659,0.0000762261,0.0003565074,0.0007349215,0.000186644,0.0003798417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004036886,0.0001785723,0.1836434,0.02860572,0.0006001806,0.0002512034,0.00002261863,8.48373e-8,0.000001474642,0.00001440361,0.001723314,0.7849187],"study_design_scores_gemma":[0.001217273,0.003482048,0.02012676,0.005358548,0.001914915,0.000595311,0.000001659379,0.00009171329,9.426602e-7,0.00004092283,0.9669873,0.0001826444],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01791043,0.9798431,0.00008357743,0.00003364173,0.0002115831,0.001124258,0.000255398,0.00003547212,0.0005024707],"genre_scores_gemma":[0.004056145,0.9949383,0.0001801525,0.0000413789,0.0002397629,0.0001383637,0.000228786,0.00005887571,0.0001182305],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.965264,"threshold_uncertainty_score":0.9999236,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127621015","doi":"10.1053/jhep.2003.50350","title":"High Body Mass Index Is An Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C","year":2003,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":359,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Body mass index; Gastroenterology; Ribavirin; Odds ratio; Risk factor; Hepatology; Overweight; Cirrhosis; Hepatitis C; Hepatitis C virus; Alanine transaminase; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.04192856396804227,"gpt":0.3592938392775276,"spread":0.3173652753094853,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004403557,0.0003273548,0.0007708312,0.0005982484,0.0001025275,0.00002659875,0.0001610641,0.0003589037,0.001228265],"category_scores_gemma":[0.0005739356,0.0003008687,0.0001386378,0.0003679936,0.00009190452,0.0001163043,0.00003919898,0.000335737,0.0003097756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001846355,"about_ca_system_score_gemma":0.001296898,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01209764,"about_ca_topic_score_gemma":0.03065612,"domain_scores_codex":[0.99669,0.0007375637,0.0004980959,0.0007432108,0.0003703323,0.0009607988],"domain_scores_gemma":[0.9983773,0.0003148574,0.00009248763,0.00067437,0.0001374464,0.0004035033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001098625,0.0003530806,0.9665211,0.00003753636,0.000101592,0.0005488997,0.0005144697,0.000004821716,0.004406492,0.0002772351,0.0002557144,0.0258804],"study_design_scores_gemma":[0.009790793,0.009638779,0.8591425,0.00004813661,0.00007476954,0.00006826734,0.00005990358,0.006625218,0.04487465,0.0004367495,0.06871309,0.0005271736],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943051,0.0001222111,0.00153671,0.0006078533,0.0002491544,0.002123127,0.0006120534,0.00006056686,0.0003831615],"genre_scores_gemma":[0.9957843,0.0005582852,0.001479036,0.0005037858,0.0001001128,0.0006162268,0.00004548912,0.00006882411,0.0008439214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1073787,"threshold_uncertainty_score":0.9999443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2072861622","doi":"10.1111/j.1572-0241.2007.01466.x","title":"FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy","year":2007,"lang":"en","type":"review","venue":"The American Journal of Gastroenterology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":355,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Liver biopsy; Cirrhosis; Receiver operating characteristic; Internal medicine; Biopsy; Hepatitis C; Gastroenterology; Hepatitis C virus; Fibrosis; Virus; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.03607926496249819,"gpt":0.3581247946315052,"spread":0.322045529669007,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002629944,0.0003532493,0.005039121,0.0003407653,0.00007058324,0.00001132757,0.0005855963,0.00009372576,0.00002764422],"category_scores_gemma":[0.02516739,0.0001762285,0.0008466974,0.0004933515,0.001174358,0.0000630286,0.0001227147,0.0007524558,0.000002281475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001220173,"about_ca_system_score_gemma":0.0003199052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001031441,"about_ca_topic_score_gemma":0.00001549124,"domain_scores_codex":[0.9947726,0.001070588,0.002960564,0.000208586,0.0005659817,0.0004216588],"domain_scores_gemma":[0.9687417,0.02399296,0.005782815,0.0006601551,0.0006498503,0.0001725294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0005533277,0.0001471482,0.003199113,0.8820578,0.001807338,0.00002764964,0.00008917217,7.804314e-7,0.00001055866,0.000004001854,0.000794075,0.111309],"study_design_scores_gemma":[0.0008601474,0.02804628,0.001101206,0.9410087,0.01162278,0.003947339,0.00006048714,0.00003960559,0.000004384931,0.000009054097,0.01320892,0.00009104278],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001143479,0.9937012,0.0004186961,0.0006704934,0.0001082402,0.00355697,0.0003853416,0.000007042179,0.000008532392],"genre_scores_gemma":[0.004339263,0.994715,0.0003079785,0.0002646167,0.000119627,0.0001549095,0.00002413808,0.00005618488,0.00001830097],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1112179,"threshold_uncertainty_score":0.983044,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2746084941","doi":"10.1016/s1473-3099(17)30496-6","title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"Hepatitis C virus research","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Gilead Sciences","keywords":"Ribavirin; Medicine; Internal medicine; Regimen; Sofosbuvir; Cirrhosis; Hepatitis C virus; Gastroenterology; Hepatitis C; Pegylated interferon; Population; Clinical endpoint; Tolerability; Clinical trial; Adverse effect; Immunology; Virus","retraction":null,"screen_n_in":null,"score":{"opus":0.1002147116584242,"gpt":0.3977524272771292,"spread":0.297537715618705,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003224714,0.0003852845,0.0009329077,0.000189106,0.0009564749,0.0005173762,0.0005485578,0.0001370651,0.0005147668],"category_scores_gemma":[0.001451534,0.0002614977,0.0001044062,0.0003141551,0.000334473,0.0006348165,0.0002514473,0.0003884557,0.00008852164],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001047628,"about_ca_system_score_gemma":0.0008489477,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02277881,"about_ca_topic_score_gemma":0.09697995,"domain_scores_codex":[0.997334,0.0002963989,0.0005085415,0.0006057431,0.0004825025,0.000772815],"domain_scores_gemma":[0.9972829,0.0004622044,0.0004088577,0.001206411,0.0003330052,0.0003066177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.470262,0.02600188,0.3540012,0.002262968,0.001193802,0.0004382313,0.001220345,0.0001498878,0.002297439,0.0002001073,0.01350463,0.1284676],"study_design_scores_gemma":[0.8007526,0.03748337,0.1279746,0.002897588,0.0009526428,0.00007075704,0.00003267474,0.01153971,0.001592961,0.0002651791,0.01542879,0.001009114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987528,0.0004212187,0.0001703636,0.000664617,0.0005053105,0.008162487,0.0008797084,0.0002520412,0.001416295],"genre_scores_gemma":[0.9913648,0.003272869,0.00008391381,0.0004690217,0.001726821,0.002304131,0.0005373357,0.00008821175,0.0001528963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3304906,"threshold_uncertainty_score":0.9999837,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}